News
ECOR
7.72
+7.52%
0.54
electroCore (ECOR) Upgraded to Buy: Here's What You Should Know
NASDAQ · 1d ago
Weekly Report: what happened at ECOR last week (1102-1106)?
Weekly Report · 1d ago
Electrocore’s Commercial Overhaul Gains Traction, Supporting a $12 Buy Case
TipRanks · 3d ago
electroCore (ECOR) Q3 2026 Earnings Call Transcript
The Motley Fool · 5d ago
CORRECTION: electroCore Widens FY2026 Sales Guidance from $41.600M to $39.000M-$42.000M vs $41.915M Est
Benzinga · 6d ago
electroCore sees FY27 revenue up 30%-40%
TipRanks · 6d ago
electroCore Sees FY 2027 revenue guidance of 30% to 40% YoY
Benzinga · 6d ago
Press Release: electroCore Announces Third -2-
Dow Jones · 6d ago
Press Release: electroCore Announces Third -3-
Dow Jones · 6d ago
*electroCore 3Q Sales $9.69M >ECOR
Dow Jones · 6d ago
H.C. Wainwright Sticks to Its Buy Rating for Electrocore (ECOR)
TipRanks · 11/03 16:15
Weekly Report: what happened at ECOR last week (1026-1030)?
Weekly Report · 11/02 09:04
ElectroCore Files FDA Submission For Quell In Persistent Chemotherapy-Related Neuropathy; Stock Up
NASDAQ · 10/28 15:39
electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy
Benzinga · 10/28 12:03
Weekly Report: what happened at ECOR last week (1019-1023)?
Weekly Report · 10/26 09:04
Weekly Report: what happened at ECOR last week (1012-1016)?
Weekly Report · 10/19 09:04
Weekly Report: what happened at ECOR last week (1005-1009)?
Weekly Report · 10/12 09:04
Electrocore’s PTSD Trial: A New Neuromodulation Angle for Investors
TipRanks · 10/08 16:31
Weekly Report: what happened at ECOR last week (0928-1002)?
Weekly Report · 10/05 09:04
Weekly Report: what happened at ECOR last week (0921-0925)?
Weekly Report · 09/28 09:04
More
Webull provides a variety of real-time ECOR stock news. You can receive the latest news about Electrocore through multiple platforms. This information may help you make smarter investment decisions.
About ECOR
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.